Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
0.3080 x 92 0.4955 x 2
Pre-market by (Cboe BZX)
0.3097 -0.0022 (-0.71%) 04/01/25 [NASDAQ]
0.3080 x 92 0.4955 x 2
Pre-market 0.3097 unch (unch) 16:00 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3000
Day High
0.3300
Open 0.3252
Previous Close 0.3119 0.3119
Volume 339,300 339,300
Avg Vol 411,890 411,890
Stochastic %K 2.04% 2.04%
Weighted Alpha -80.10 -80.10
5-Day Change -0.1205 (-28.01%) -0.1205 (-28.01%)
52-Week Range 0.3000 - 3.4500 0.3000 - 3.4500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,168
  • Shares Outstanding, K 71,075
  • Annual Sales, $ 570 K
  • Annual Income, $ -26,430 K
  • EBIT $ -62 M
  • EBITDA $ -61 M
  • 60-Month Beta 0.29
  • Price/Sales 43.95
  • Price/Cash Flow N/A
  • Price/Book 0.36
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.38
  • Most Recent Earnings $-0.13 on 03/11/25
  • Next Earnings Date 05/13/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 475.96% ( +69.37%)
  • Historical Volatility 82.46%
  • IV Percentile 74%
  • IV Rank 45.81%
  • IV High 930.51% on 02/28/25
  • IV Low 91.73% on 05/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 925
  • Open Int (30-Day) 988

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 4
  • High Estimate -0.13
  • Low Estimate -0.15
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3000 +3.23%
on 04/01/25
Period Open: 0.5300
0.5800 -46.60%
on 03/10/25
-0.2203 (-41.57%)
since 02/28/25
3-Month
0.3000 +3.23%
on 04/01/25
Period Open: 0.9337
1.0200 -69.64%
on 01/03/25
-0.6240 (-66.83%)
since 12/31/24
52-Week
0.3000 +3.23%
on 04/01/25
Period Open: 3.0900
3.4500 -91.02%
on 04/30/24
-2.7803 (-89.98%)
since 04/01/24

Most Recent Stories

More News
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

OVID : 0.3097 (-0.71%)
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

OVID : 0.3097 (-0.71%)
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

OVID : 0.3097 (-0.71%)
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

OVID : 0.3097 (-0.71%)
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

OVID : 0.3097 (-0.71%)
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

OVID : 0.3097 (-0.71%)
Ovid Therapeutics to Host Investor Event

OVID : 0.3097 (-0.71%)
3 'Strong Buy'-Rated Stocks to Buy Now on the Dip

These outstanding growth stocks are worth buying on the dip.

AMZN : 192.17 (+1.00%)
$SPX : 5,633.07 (+0.38%)
GEHC : 79.57 (-1.41%)
GD : 274.14 (+0.57%)
OVID : 0.3097 (-0.71%)
TAK : 14.90 (+0.20%)
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the...

OVID : 0.3097 (-0.71%)
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate...

OVID : 0.3097 (-0.71%)

Business Summary

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved...

See More

Key Turning Points

3rd Resistance Point 0.3565
2nd Resistance Point 0.3432
1st Resistance Point 0.3265
Last Price 0.3097
1st Support Level 0.2965
2nd Support Level 0.2832
3rd Support Level 0.2665

See More

52-Week High 3.4500
Fibonacci 61.8% 2.2467
Fibonacci 50% 1.8750
Fibonacci 38.2% 1.5033
Last Price 0.3097
52-Week Low 0.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies